CClinicalTrials.gg
CompletedNCT06506500Updated Jul 17, 2024

Unilateral Biportal Endoscopy Lumbar Interbody Fusion (ULIF) Versus Posterior Lumbar Interbody Fusion (PLIF) in Management of Single Level Lumbar Degenerative Disease: A Retrospective Study

An observational study in Lumbar Degenerative Disease, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2024-07-17.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
140
Sex
All
01

Study summary

The study aimed to compare the clinical efficacy and safety of unilateral biportal endoscopic lumbar interbody fusion (ULIF) with posterior lumbar interbody fusion (PLIF) in the treatment of single-level lumbar degenerative diseases.

02

Conditions studied

  • Lumbar Degenerative Disease
03

In context

Lead sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 466 studies on the registry; 271 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

  1. Patients who have been diagnosed with lumbar disc herniation, lumbar spinal stenosis, or lumbar spondylolisthesis.
  2. The patient has clear indications for surgical treatment.
  3. The patient is undergoing their initial single-segment ULIF or PLIF surgery at our hospital.

Inclusion criteria

  1. Patients who have been diagnosed with lumbar disc herniation, lumbar spinal stenosis, or lumbar spondylolisthesis based on their medical history, physical signs, and imaging exams such as lumbar anteroposterior and lateral radiographs (including hyperextension and hyperflexion positions), lumbar CT, and lumbar MR. (2) The patient has clear indications for surgical treatment: ① Conservative treatment for more than three months has been ineffective or the symptoms have continued to worsen ② The patient's symptoms are severe and interfere with their daily work and life ③ The patient exhibits signs of cauda equina nerve compression (such as numbness in the perineal area, loss of bowel and bladder control, etc.).

(3) The patient is undergoing their initial single-segment ULIF or PLIF surgery at our hospital.

Exclusion criteria

Exclusion Criteria:

  1. Patients with lumbar degenerative diseases involving two or more segments
  2. Pathological changes caused by other diseases, such as spinal infections, spinal trauma, spinal tumors, neurological diseases, etc.
  3. Patients with lumbar spondylolisthesis exceeding Meyerding Grade II or degenerative scoliosis with a Cobb angle greater than 20 degrees
  4. History of previous lumbar surgery
  5. History of previous tumor disease.
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
140 participants (actual)
Patient registry
No

Groups and cohorts

  • ULIF

    Unilateral Biportal Endoscopy Lumbar Interbody Fusion

  • PLIF

    Posterior Lumbar Interbody Fusion

06

What researchers measure

Primary outcomes

  1. ODI

    Oswestry Disability Index

    Time frame: before surgery,1-week,1-month,3-month,6-month and 1-year postoperative

07

Study locations

1 site
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
    Guangzhou, Guangdong 512000, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06506500
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Responsible party
Sponsor
First posted
Jul 17, 2024
Start date
Nov 1, 2022
Primary completion
Sep 1, 2023
Completion
May 1, 2024
Last update
Jul 17, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion